ProNAi Therapeutics, Inc. Names Polymun Scientific Immunbiologische Forschung GmbH as Preferred Manufacturer of PNT2258 DNAi(R)-based Cancer Therapeutic

Published: Jun 14, 2007

KALAMAZOO, Mich. & VIENNA, Austria--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced that it has signed a supply agreement with Polymun Scientific GmbH, an Austrian contract biopharmaceutical developer, to manufacture the company’s PNT2258 DNAi®-based cancer therapeutic.

Back to news